Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer’s disease  

作　　者：Leonardo Brunetti Antonio Laghezza Fulvio Loiodice Paolo Tortorella Luca Piemontese 

机构地区：[1]Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro"

出　　处：《Neural Regeneration Research》2020年第1期67-68,共2页中国神经再生研究（英文版）

摘　　要：Alzheimer’s disease(AD)is a widespread pathology described for the first time by Alois Alzheimer in 1907.It can be classified as a neurodegenerative disease consisting in a progressive loss of memory and cognitive functions,whose prevalence is estimated to grow due to the increasing life expectancies all over the world.To date,the only treatments available for this disease are symptomatic and no actual effective cure is available.The main effect of the drugs commonly used in therapeutic protocols is to temporarily delay the onset of the disease and to slightly improve the patients’cognitive capabilities(Piemontese,2017)(Figure 1).

关 键 词：ALZHEIMER drugs TREATMENT 

分 类 号：R74[医药卫生—神经病学与精神病学]